Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald R Galluppi

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Neurology and Therapy|March 18, 2023
Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in HumansYu-Luan Chen, Hironobu Tsukada, Snezana Milanovic, et al.
Clinical and Translational Science|March 23, 2023
A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophreniaHironobu Tsukada, Snezana M Milanovic, Borje Darpo, et al.
Clinical Pharmacokinetics|October 26, 2023
A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy SubjectsHironobu Tsukada, Yu-Luan Chen, Guangqing Xiao, et al.
Investigational New Drugs|January 25, 2014
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsMargaret von Mehren, Carolyn D Britten, Peter Pieslor, et al.
Journal of Clinical Pharmacology|June 6, 2022
ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case StudiesBorje Darpo, Marie Borin, Georg Ferber, et al.
Clinical Pharmacology and Therapeutics|March 23, 2024
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting ProgramGerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, et al.
Clinical Pharmacology and Therapeutics|June 1, 2024
Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the BrainSeth C Hopkins, Siriporn Toongsuwan, Taryn J Corriveau, et al.
Toxicologic Pathology|May 8, 2010
Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dogDale L Morris, Shawn P O'Neil, Rajesh V Devraj, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Neurology and Therapy|March 18, 2023
Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in HumansYu-Luan Chen, Hironobu Tsukada, Snezana Milanovic, et al.
Clinical and Translational Science|March 23, 2023
A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophreniaHironobu Tsukada, Snezana M Milanovic, Borje Darpo, et al.
Clinical Pharmacokinetics|October 26, 2023
A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy SubjectsHironobu Tsukada, Yu-Luan Chen, Guangqing Xiao, et al.
Investigational New Drugs|January 25, 2014
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsMargaret von Mehren, Carolyn D Britten, Peter Pieslor, et al.
Journal of Clinical Pharmacology|June 6, 2022
ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case StudiesBorje Darpo, Marie Borin, Georg Ferber, et al.
Clinical Pharmacology and Therapeutics|March 23, 2024
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting ProgramGerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, et al.
Clinical Pharmacology and Therapeutics|June 1, 2024
Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the BrainSeth C Hopkins, Siriporn Toongsuwan, Taryn J Corriveau, et al.
Toxicologic Pathology|May 8, 2010
Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dogDale L Morris, Shawn P O'Neil, Rajesh V Devraj, et al.
Pageof 2